DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Beryl Drugs Ltd (BERLDRG) share price today?

Beryl Drugs Ltd (BERLDRG) is trading at ₹22 on the BSE, down 0.90% on the day. Source: DocStoX.

What is the PE ratio of Beryl Drugs Ltd?

Beryl Drugs Ltd has a price-to-earnings (PE) ratio of 19.3 in the Healthcare sector.

What is the market capitalisation of Beryl Drugs Ltd?

Beryl Drugs Ltd has a market capitalisation of approximately ₹11 crore.

Beryl Drugs Ltd

BERLDRG·BSE·Healthcare

₹22.00▼ -0.20 (-0.90%)

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Day₹20.72

₹22.20

52W₹16

₹3043%

Open

₹20.90

High

₹22.20

Low

₹20.72

Prev Close

₹22.20

Volume

1.5K

VWAP

₹21.48

Snapshot

Key fundamentals

Market Cap

₹11 Cr

P/E Ratio

19.30Fair

P/B Ratio

1.14

EPS

₹1.14

Book Value

₹19.44

ROE

6.09%Weak

ROCE

10.15%Decent

Dividend Yield

0.00%

Debt / Equity

0.25Low

Face Value

₹10.00

52W High

₹30.00

52W Low

₹15.92

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Expensive

None moatMedium uncertainty

Fair value estimate

₹19

▼ 13.2%downside

Trading at ₹22 — 13% above our estimate

BearFair valueBull

₹16₹19₹23

/100

Business quality — Watch the fundamentals

Growth 50Profitability 5Efficiency 11Valuation 82

Plain English

Our view

A steady, established business
Low debt relative to equity
Weak returns on equity (6%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

19.3Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

6.1%Weak

Above 15% is considered healthy for Indian equities

ROCE

10.2%Decent

Above 18% means capital is working hard

Debt/Eq

0.25Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹11 Cr

P/B

1.14

EPS

₹1.14

Div Yield

—

What changed

Recent changes

Promoters+0.34% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 19.3×

Growth

Shrinking

-11% rev CAGR

Profitability

Modest

6.1% ROE

Financial health

Rock solid

D/E 0.25

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹33,272 Cr

Trades10

VWAP₹21.48

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-11.2%

+6.0%

10Y

+3.8%

Profit

-14.6%

+14.9%

10Y

+10.9%

EPS

-7.6%

+20.6%

10Y

+13.4%

Profile

Pros

Company has reduced debt.
Stock is trading at 1.14 times its book value
Debtor days have improved from 79.1 to 39.5 days.
Company's working capital requirements have reduced from 55.1 days to 39.3 days

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of 6.60% over past five years.
Promoter holding is low: 27.8%
Company has a low return on equity of 6.42% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Promoters raised their stake by 0.34 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

28%

Promoter

Promoters

27.8%+0.34

Public

63.6%-1.38

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

8.6%

Total shareholders

7,309-40 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter27.82%

Public63.56%

Others8.62%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1993, Beryl Drugs Ltd is in the business of pharmaceuticals manufacturing[1]

Beryl Drugs Ltd valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

Beryl Drugs Ltd peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Ltd Divis Laboratories Ltd Torrent Pharmaceuticals Ltd Apollo Hospitals Enterprise Ltd Zydus Lifesciences Ltd Cipla Ltd Lupin Ltd Max Healthcare Institute Ltd Mankind Pharma Ltd Dr Reddys Laboratories Ltd Aurobindo Pharma Ltd Laurus Labs Ltd

Compare Beryl Drugs Ltd with peers

Beryl Drugs Ltd vs Sun Pharmaceutical Industries Ltd Beryl Drugs Ltd vs Divis Laboratories Ltd Beryl Drugs Ltd vs Torrent Pharmaceuticals Ltd Beryl Drugs Ltd vs Apollo Hospitals Enterprise Ltd Beryl Drugs Ltd vs Zydus Lifesciences Ltd Beryl Drugs Ltd vs Cipla Ltd

Related tools & concepts

Value Beryl Drugs Ltd with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Beryl Drugs Ltd

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

Beryl Drugs Ltd valuation & research

Beryl Drugs Ltd peers in Healthcare

Compare Beryl Drugs Ltd with peers

Related tools & concepts

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions